TABLE 1.
Baseline characteristics of the two groups
| No. | IG | OG | p | Unweighted standardized mean difference | Weighted standardized mean difference | ||
|---|---|---|---|---|---|---|---|
| 203 | 99 | ||||||
| Female, n (%) | 130 | (64.0) | 72 | (72.7) | 0.132 | −0.087 | −0.184 |
| Age, years, mean (SD) | 55.1 | (4.8) | 55.0 | (5.0) | 0.896 | 0.082 | 0.16 |
| Monofocal onset, n (%) | 195 | (96) | 96 | (97) | 0.692 | −0.009 | −0.048 |
| EDSS at baseline, median (q1–q3) | 2.0 | (1.5–3.0) | 2.5 | (1.5–3.0) | 0.492 | −0.11 | −0.084 |
| Relapses in the year before treatment start, n (%) | 179 | (88.2) | 89 | (89.9) | 0.657 | −0.017 | 0.174 |
| DD, median (q1–q3) | 58 | (18–167) | 70.5 | (22–195) | 0.982 | 2.12 | 0.0002 |
Abbreviations: DD, disease duration; EDSS, Expanded Disability Status Scale; IG, injectable group; OG, oral group, q1‐q3, first and third quartiles.
*Only in patients with relapses in the last year.